Patients & Physicians
Phase 3 SURPASS-IPF: Advancing the first head-to-head superiority trial in IPF
Phase 3 SURPASS-IPF (NCT07284602) reflects our belief that deupirfenidone has the potential to become a new standard of care for IPF. The study combines a rigorous head-to-head evaluation against pirfenidone with a patient-centric design that ensures all participants receive active treatment.
Pivotal Phase 3 global, randomized, double-blind, head-to-head trial powered to evaluate the superiority of deupirfenidone against the FDA-approved treatment, pirfenidone
No placebo arm, allowing every participant to receive an active treatment
Builds on the same active comparator design and dosing regimen used in the completed Phase 2b ELEVATE IPF trial
Explore Phase 3 SURPASS-IPF
Learning from people living with IPF
As part of our commitment to the IPF community, we’ve identified critical barriers to treatment, opportunities for improved community engagement, and the need for patient-centered approaches in the development of new therapeutics. These learnings, published in BMC Pulmonary Medicine, have been incorporated into our development plans for deupirfenidone.
This research was conducted in collaboration with Tejaswini Kulkarni, MD, MPH, from the University of Alabama at Birmingham, Lisa Lancaster, MD, from Vanderbilt University Medical Center, and Jessica Shore, RN, PhD, from the Pulmonary Fibrosis Foundation (PFF).
"By integrating the perspectives of people with IPF into every stage of diagnosis, disease management, education, and clinical development, we have a real opportunity to shift the paradigm for IPF care to one that is more empathetic, effective, and aligned with the realities of living with this serious disease. This study is just the beginning; academic centers, professional societies, advocacy organizations, and pharmaceutical companies need to continue to collaborate on patient-informed innovation that bridges the current gaps in diagnosis, treatment, and quality of life."
Camilla Graham, MD, MPH
Medical Affairs
